AU1521501A - Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders - Google Patents

Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Info

Publication number
AU1521501A
AU1521501A AU15215/01A AU1521501A AU1521501A AU 1521501 A AU1521501 A AU 1521501A AU 15215/01 A AU15215/01 A AU 15215/01A AU 1521501 A AU1521501 A AU 1521501A AU 1521501 A AU1521501 A AU 1521501A
Authority
AU
Australia
Prior art keywords
caspase
diagnose
modulators
eye
treat skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU15215/01A
Inventor
Wim Declercq
Saskia Lippens
Peter Vandenabeele
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of AU1521501A publication Critical patent/AU1521501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
AU15215/01A 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders Abandoned AU1521501A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP99203752 1999-11-10
EP99203752 1999-11-10
EP00202776 2000-08-04
EP00202776 2000-08-04
PCT/EP2000/011251 WO2001034183A2 (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Publications (1)

Publication Number Publication Date
AU1521501A true AU1521501A (en) 2001-06-06

Family

ID=26072576

Family Applications (1)

Application Number Title Priority Date Filing Date
AU15215/01A Abandoned AU1521501A (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Country Status (4)

Country Link
EP (1) EP1227834A2 (en)
AU (1) AU1521501A (en)
CA (1) CA2390510A1 (en)
WO (1) WO2001034183A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384469A1 (en) * 2002-07-25 2004-01-28 Cognis France S.A. Method for protecting and for modulating tight junctions
EP1384468A1 (en) * 2002-07-25 2004-01-28 Cognis France S.A. Method for protecting and for modulating tight junctions
AU2007291199A1 (en) * 2006-09-01 2008-03-06 Universiteit Gent Pharmaceutical and sunscreen compositions comprising caspase-14
JP5562015B2 (en) * 2009-12-04 2014-07-30 株式会社 資生堂 Screening method for skin barrier function recovery promoting substance

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
GB8719988D0 (en) * 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
KR920002163B1 (en) * 1988-08-05 1992-03-19 온코겐, 어 리미티드 파트너쉽 Psoriasis treatment with tgf-beta
WO1992013551A1 (en) * 1991-02-04 1992-08-20 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
FR2726187A1 (en) * 1994-10-26 1996-05-03 Jean Noel Thorel Topical compsns. contg. calcium chloride
US5716627A (en) * 1996-04-25 1998-02-10 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester
US6432628B1 (en) * 1997-08-26 2002-08-13 Thomas Jefferson University Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
JP2001521730A (en) * 1997-10-30 2001-11-13 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド Caspase-14 polypeptide
AU763721B2 (en) * 1998-07-17 2003-07-31 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue

Also Published As

Publication number Publication date
WO2001034183A3 (en) 2001-11-08
WO2001034183A2 (en) 2001-05-17
CA2390510A1 (en) 2001-05-17
EP1227834A2 (en) 2002-08-07

Similar Documents

Publication Publication Date Title
AU2001236904A1 (en) Deep brain stimulation system for the treatment of parkinson's disease or other disorders
AU2001288628A1 (en) Method and reagents for treatment of skin disorders by modulating the notch pathway
AU6530600A (en) Use of neurotoxin for treating cardiac muscle disorders
EP1648385A4 (en) System and method for the photodynamic treatment of burns, wounds, and related skin disorders
AU5255499A (en) Systems and methods for electrosurgical treatment of tissue in the brain and spinal cord
IL150548A0 (en) Brain, spinal and nerve injury treatment
AU2001288251A1 (en) Methods and devices for optical stimulation of neural tissues
IL165397A0 (en) Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
IL127943A0 (en) Pharmaceutical and cosmetic composition for the treatment of skin disorders
AU2001271887A1 (en) Methods for diagnosis and treatment of psychiatric disorders
AU4363600A (en) Treatment of and/or prophylaxis against brain and spinal cord injury
AU1521501A (en) Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
AU7106300A (en) Treatment of skin disorders
WO2002013805A3 (en) Method of treating neurodegenerative disorders of the retina and optic nerve head
WO2001043697A3 (en) Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
AU6241096A (en) A cosmetic antimycotic composition for skin applications and pharmaceutical composition for the treatment of tumorous cells, bladder or nerve disorders
ID23175A (en) THE USE OF BENZOPIRANOL TO TREAT NERVE DISORDERS
AU6968098A (en) Topical treatment of skin diseases and eye afflictions
IL131347A0 (en) Treatment of skin disorders
AR026062A1 (en) TREATMENT OF EYE DISORDERS
GB2370507B (en) Apparatus for the diagnosis and therapy of neuro-muscular and other tissue disorders
AU2002246117A1 (en) Method for treatment and diagnosis of eye tissues
AU2509801A (en) Method for the cosmetic treatment of human skin
AU2002361516A1 (en) Ophthalmic rofecoxib suspension for the treatment of ocular pain and inflammation
AU4332900A (en) Use of interleukin-11 to treat gastrointestinal disorders

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase